Journal of Thrombosis and Thrombolysis

, Volume 37, Issue 3, pp 331–337 | Cite as

Warfarin use and long-term outcomes in patients with acute myocardial infarction and atrial fibrillation

  • James A. Nelson
  • John P. Vavalle
  • Christopher H. May
  • Aijing Zhang
  • L. Kristin Newby
  • Linda K. Shaw
  • Sana M. Al-Khatib
  • John H. Alexander
  • Christopher B. Granger
  • Renato D. Lopes
Article

Abstract

Warfarin use in patients with acute myocardial infarction (AMI) and atrial fibrillation (AF) remains challenging. We describe use of warfarin up to 1 year after hospitalization among patients with AMI and AF according to stroke and bleeding risk, and identify factors associated with long-term mortality in this population. Patients with AMI and AF who underwent cardiac catheterization during their AMI hospitalization in 1995–2007 were identified from the Duke Databank for Cardiovascular Disease. Warfarin use at discharge, 6 months, and 1 year as well as long-term vital status were assessed by surveys. Rates of warfarin use were presented according to CHADS2 and CHA2DS2VASc stroke and ATRIA bleeding risk scores. Cox proportional hazards modeling was used to determine whether warfarin use at discharge was independently associated with 1-year mortality. A total of 879 patients hospitalized with AMI with AF were identified. Median age was 72 (25th, 75th percentiles: 64, 79), and median follow-up was 4.1 years (1.3, 7.4). The rate of warfarin use at discharge was 24 % and did not differ by CHADS2, CHA2DS2VASc, or ATRIA risk scores. Warfarin use remained similar at 6 months (26 %) and 1 year (27 %). Long-term mortality was high and did not differ by whether warfarin was or was not prescribed at discharge (72 and 71 %, respectively). Factors associated with 1-year mortality were history of heart failure (HR 1.58, 95 % CI 1.32–1.90), higher Charlson comorbidity index (HR 1.19, 95 % CI 1.11–1.28), and older age (HR 1.03 per 1-year increase, 95 % CI 1.02–1.05). Warfarin use at discharge among patients hospitalized for AMI who had comorbid AF was low and remained low at 1 year. Warfarin use at hospital discharge was not associated with either 1-year mortality or long-term mortality.

Keywords

Atrial fibrillation Acute myocardial infarction Warfarin Antiplatelet therapy 

References

  1. 1.
    Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22:983–988PubMedCrossRefGoogle Scholar
  2. 2.
    Wong CK, White HD, Wilcox RG et al (2000) New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. Am Heart J 140:878–885PubMedCrossRefGoogle Scholar
  3. 3.
    Jabre P, Roger VL, Murad MH et al (2011) Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis. Circulation 123:1587–1593PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Lopes RD, Pieper KS, Horton JR et al (2008) Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. Heart 94:867–873PubMedCrossRefGoogle Scholar
  5. 5.
    Jabre P, Jouven X, Adnet F et al (2011) Atrial fibrillation and death after myocardial infarction: a community study. Circulation 123:2094–2100PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Mohr JP, Thompson JL, Lazar RM et al (2001) A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 345:1444–1451PubMedCrossRefGoogle Scholar
  7. 7.
    Anderson JL, Adams CD, Antman EM et al (2011) ACCF/AHA Focused Update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 123:e426–e579PubMedCrossRefGoogle Scholar
  8. 8.
    Petersen P, Boysen G, Godtfredsen J et al (1989) Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1:175–179PubMedCrossRefGoogle Scholar
  9. 9.
    Huber K, Airaksinen KJ, Cuisset T et al (2011) Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb Haemost 106:569–571PubMedCrossRefGoogle Scholar
  10. 10.
    Gage BF, Waterman AD, Shannon W et al (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285:2864–2870PubMedCrossRefGoogle Scholar
  11. 11.
    Lip GY, Nieuwlaat R, Pisters R et al (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137:263–272PubMedCrossRefGoogle Scholar
  12. 12.
    Fang MC, Go AS, Chang Y et al (2011) A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study. J Am Coll Cardiol 58:395–401PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383PubMedCrossRefGoogle Scholar
  14. 14.
    Al-Khatib SM, Pieper KS, Lee KL et al (2001) Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: results from the PURSUIT trial. Am J Cardiol 88:76–79CrossRefGoogle Scholar
  15. 15.
    Stenestrand U, Lindback J, Wallentin L (2005) Anticoagulation therapy in atrial fibrillation in combination with acute myocardial infarction influences long-term outcome: a prospective cohort study from the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA). Circulation 112:3225–3231PubMedCrossRefGoogle Scholar
  16. 16.
    Lip G, Huber K, Andreotti F, Arnesen H, Airaksinen K, Cuisset T, Kirchhof P, Marín F (2010) Consensus Document of European Society of Cardiology Working Group on Thrombosis. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary–a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 31:1311–1318PubMedCrossRefGoogle Scholar
  17. 17.
    Faxon DP, Eikelboom JW, Berger PB, Holmes DRJ, Bhatt DL, Moliterno DJ, Becker RC, Angiolillo DJ (2011) Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North-American perspective. Thromb Haemost 106:572–584PubMedCrossRefGoogle Scholar
  18. 18.
    Hansen ML, Sørensen R, Clausen MT et al (2010) Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 170:1433–1441PubMedCrossRefGoogle Scholar
  19. 19.
    Sorensen R, Hansen ML, Abildstrom SZ et al (2009) Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 374:1967–1974PubMedCrossRefGoogle Scholar
  20. 20.
    Dewilde WJ, Oirbans T, Verheugt FW et al (2013) Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381:1107–1115PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • James A. Nelson
    • 1
  • John P. Vavalle
    • 1
  • Christopher H. May
    • 2
  • Aijing Zhang
    • 1
  • L. Kristin Newby
    • 1
  • Linda K. Shaw
    • 1
  • Sana M. Al-Khatib
    • 1
  • John H. Alexander
    • 1
  • Christopher B. Granger
    • 1
  • Renato D. Lopes
    • 1
  1. 1.Duke Clinical Research InstituteDurhamUSA
  2. 2.The Cleveland Clinic FoundationClevelandUSA

Personalised recommendations